Life Sciences Tools and Services
Company Overview of Cancer Research Technology Limited
Cancer Research Technology Limited develops and commercializes new discoveries in cancer research. The company translates academic research into industry propositions for the benefit of cancer patients. Its services include project development, such as project identification, protecting materials, patent filing, project development, marketing, licensing and partnering, and post-signature management; commercialization, including licensing and spin-outs, collaboration, alliances, and consortia; small molecule drug discovery; clinical development services through clinical development partnerships; imaging and diagnostics research services; and funding services. The company also provides Ximbio,...
407 St John Street
London, EC1V 4AD
Founded in 1982
Key Executives for Cancer Research Technology Limited
Chief Executive Officer and Director
Chief Operating Officer, Director and Chief Executive of Cancer Research Uk
Head of Medicinal Chemistry
Head of Clinical Partnerships
Head of Functional Pharmacology
Compensation as of Fiscal Year 2016.
Cancer Research Technology Limited Key Developments
IDBS and Cancer Research Technology Collaborates to Streamline Plate Correction
Aug 10 16
IDBS and Cancer Research Technology have collaborated to streamline plate correction in high throughput screening (HTS). The algorithm, developed by IDBS in response to CRT requirements and soon to be offered to all customers, enables ActivityBase users to correct data within acceptable margins in seconds. It improves data quality and reduces the number of results that would otherwise need to be corrected manually or reworked, resulting in significant time and cost savings. The ActivityBase template enables the automated correction of fifty plates in two seconds, with researchers able to view and store both 'before' and 'after' data. The functionality is compatible with data containing control wells as well as for multiple plate layouts.
Cancer Research Technology, Birmingham University and Alta Innovations Collaborate to Commercialize Cancer Research
Aug 9 16
Cancer Research Technology (CRT) has signed an agreement with the University of Birmingham and its commercial division Alta Innovations (Alta) to work in collaboration to develop and commercialise the university’s cancer research. The two-year agreement is focused on speeding up commercialisation of the University of Birmingham’s major cancer research into diagnostics, treatments and technologies that can benefit patients. Under the deal, Alta will work in close cooperation with the scientists at the university with an aim to recognise most promising cancer research opportunities. CRT, on the other hand, will use its expertise to commercialise cancer research and its vast network across the pharmaceutical and biotechnology industry in order to identify and translate promising research at the university. CRT will work with Alta and the University of Birmingham’s academics in a bid to promising cancer opportunities, along with the major clinical expertise available and the university’s primary research in areas such as immunology and genomics. The financial benefits received from the research will be shared between CRT and the University of Birmingham. CRT will use its financial returns to invest in Cancer Research UK’s life-saving research, while the University of Birmingham will be used for the benefit of the educational charity.
Ignyta, Inc. and Cancer Research Technology Limited to Terminate the License Agreement
Apr 8 16
Effective as of April 8, 2016, Ignyta, Inc. and Cancer Research Technology Limited mutually agreed to terminate the License agreement between the company and CRT dated as of January 20, 2014 (the CRT Agreement). The termination of the CRT agreement was due to the company's prior determination to cease all development activities relating to its RXDX-108 program. The parties have agreed to cooperate in an orderly transition of the RXDX-108 program and related information and assets to CRT, including all related intellectual property rights. The company does not expect to incur any material expenses in connection with the termination of the CRT agreement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|